News
SILK
38.65
0.00%
0.00
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
Benzinga · 03/10 15:00
Citigroup Upgrades Silk Road Medical to Neutral
Benzinga · 03/10 10:42
Citigroup upgrades Silk Road Medical (SILK) to a Hold
TipRanks · 03/10 08:55
SILK Makes Notable Cross Below Critical Moving Average
NASDAQ · 03/09 18:21
Silk Road Medical: Today Best Nearby Cap-Gain Medical Equipment Stock Prospect
Seeking Alpha · 03/05 15:45
Silk Road Medical Becomes Oversold (SILK)
NASDAQ · 03/02 21:40
Bank of America Securities Sticks to Their Buy Rating for Silk Road Medical (SILK)
TipRanks · 03/01 11:05
Silk Road Medical's Q4 Loss Narrows, Revenue Rises
Silk Road Medical's Q4 Loss Narrows, Revenue Rises
MT Newswires · 03/01 03:34
Silk Road Medical GAAP EPS of -$0.34 beats by $0.04, revenue of $40.07M beats by $2.72M
Seeking Alpha · 02/28 21:51
Silk Road Medical Q4 EPS $(0.34) Beats $(0.38) Estimate, Sales $40.07M Beat $37.35M Estimate
Benzinga · 02/28 21:36
-- Earnings Flash (SILK) SILK ROAD MEDICAL Posts Q4 Revenue $40.1M, vs. Street Est of $37.3M
-- Earnings Flash (SILK) SILK ROAD MEDICAL Posts Q4 Revenue $40.1M, vs. Street Est of $37.3M
MT Newswires · 02/28 16:21
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 02/27 22:35
Capital World Investors Cuts Stake in Silk Road Medical (SILK)
NASDAQ · 02/13 19:54
Wolfe Research Downgrades Silk Road Medical to Peer Perform
Benzinga · 02/07 11:44
Healthcare Outlook 2023
Seeking Alpha · 01/23 15:02
Insider Sell: Silk Road Medical
Insider Sell: Silk Road Medical
MT Newswires · 01/20 01:35
Argus Research Adjusts Silk Road Medical's Price Target to $70 From $60, Maintains Buy Rating
Argus Research Adjusts Silk Road Medical's Price Target to $70 From $60, Maintains Buy Rating
MT Newswires · 01/09 13:37
Silk Road Medical (SILK) is a Great Momentum Stock: Should You Buy?
Does Silk Road Medical (SILK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 12/05/2022 17:00
Silk Road Medical (SILK) Reports Q3 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) delivered earnings and revenue surprises of 34.09% and 10.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09/2022 00:35
More
Webull provides a variety of real-time SILK stock news. You can receive the latest news about Silk Road Medical through multiple platforms. This information may help you make smarter investment decisions.
About SILK
Silk Road Medical, Inc. is a medical device company, which is focused on reducing the risk of stroke and its devastating impact. The Company has discovered an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR), which relies on two concepts: minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain and combines the benefits of innovative endovascular techniques with fundamental surgical principles. The Company's ENROUTE Transcarotid Neuroprotection System (NPS) and ENROUTE Transcarotid Stent System are the products for use in TCAR. Its ENROUTE Transcarotid Stent System is placed during a period of temporary high-rate blood flow reversal, which is enabled by its ENROUTE Transcarotid NPS. It markets and sells its products in the United States through a direct sales organization consisting of approximately 64 sales representatives and 62 clinical support specialists.